Antigen- and/or immune-driven lymphoproliferative disorders

Annals of Oncology

Volumn 14, Issue 11, 2003, Pages 1595-1606

  Aljurf, Mahmoud D ^a   Owaidah, T W ^a   Ezzat, A ^a   Ibrahim, E ^a   Tbakhi, A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Infection; Lymphoma; Lymphoproliferative disorder

Indexed keywords

ANTIGEN; ANTIPARASITIC AGENT; CASEIN KINASE; LATENT MEMBRANE PROTEIN 1; MYC PROTEIN; PHENYTOIN; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ALEUTIAN MINK DISEASE; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANIMAL PARASITOSIS; ANISAKIS; AVIAN LEUKOSIS ONCOVIRUS; B CELL LYMPHOMA; BIRD DISEASE; BORRELIA BURGDORFERI; BURKITT LYMPHOMA; CATTLE DISEASE; CELIAC DISEASE; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MODEL; EPSTEIN BARR VIRUS; FASCIOLA; GENE OVEREXPRESSION; HAIRY CELL LEUKEMIA; HELICOBACTER PYLORI; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INTESTINE LYMPHOMA; LEUKEMIA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOSIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MEDLINE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; ORGAN TRANSPLANTATION; PARVOVIRUS; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOLYMPHOMA; REVIEW; SJOEGREN SYNDROME; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; THEILERIA PARVA; VIRUS LATENCY;

ANIMALS; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; VIRUS DISEASES;

EID: 0345256498     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg442     Document Type: Review

References (177)

1. Hayward WS, Neel BG, Astrin SM. Activation of a cellular oncogene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981; 290: 475-480.
2. Cleary ML, Nalesnik MA, Shearer WT, Sklar J. Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus. Blood 1988; 72: 349-352.
3. Bahler DW, Levy R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc Natl Acad Sci USA 1992; 89: 6770-6774.
4. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB et al. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 1991; 138: 149-163.
5. Roggero E, Zucca E, Pinotti G et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995; 122: 767-769.
6. Garbe C, Stein H, Dienemann D, Orfanos CE. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991; 24: 584-590.
7. Abratt RP, Sealy R, Uys CJ, Lawson R. Lymphadenopathy associated with diphenylhydantoin therapy. Clin Oncol (R Coll Radiol) 1982; 8: 351-356.
8. Yamaguchi K. Human T-lymphotropic virus type I in Japan. Lancet 1994; 343: 213-216.
9. Baddoura FK, Unger ER, Mufarrij A et al. Latent Epstein-Barr virus infection is an unlikely event in the pathogenesis of immunoproliferative small intestinal disease. Cancer 1994; 74: 1699-1705.
10. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-620.
11. Wilson JB, Levine AJ. The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Curr Top Microbiol Immunol 1992; 182: 375-384.
12. Zucca E, Bertoni F, Roggero E et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998; 338: 804-810.
13. Kamel OW, van de RM, Hanasono MM, Warnke RA. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma 1995; 16: 363-368.
14. Gaidano G, Pastore C, Gloghini A et al. AIDS-related non-Hodgkin's lymphomas: molecular genetics, viral infection and cytokine deregulation. Acta Haematol 1996; 95: 193-198.
15. Toren A, Ben-Bassat I, Rechavi G. Infectious agents and environmental factors in lymphoid malignancies. Blood Rev 1996; 10: 89-94.
16. ole-MoiYoi OK. Casein kinase II in theileriosis. Science 1995; 267: 834-836.
17. Seldin DC, Leder P. Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 1995; 267: 894-897.
18. Porter DD. Aleutian disease: a persistent parvovirus infection of mink with a maximal but ineffective host humoral immune response. Prog Med Virol 1986; 33: 42-60.
19. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 338: 1413-1421.
20. Kerr BM, Lear AL, Rowe M et al. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 1992; 187: 189-201.
21. Rowe M, Lear AL, Croom-Carter D et al. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 1992; 66: 122-131.
22. Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587.
23. Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997; 2: 33-40.
24. Cleary ML, Warnke R, Sklar J. Monoclonality of lymphoproliferative lesions in cardiac-transplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements. N Engl J Med 1984; 310: 477-482.
25. Knowles DM. The molecular genetics of post-transplantation lymphoproliferative disorders. Springer Semin Immunopathol 1998; 20: 357-373.
26. Chadburn A, Chen JM, Hsu DT et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998; 82: 1978-1987.
27. Cleary ML, Sklar J. Lymphoproliferative disorders in cardiac transplant recipients are multiclonal lymphomas. Lancet 1984; 2: 489-493.
28. Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
29. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
30. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
31. Savoie A, Perpete C, Carpentier L et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715-2722.
32. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998; 91: 3079-3083.
33. Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654-3661.
34. Fischer A, Blanche S, Le Bidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451-1456.
35. Shapiro RS, Chauvenet A, McGuire W et al. Treatment of B-cell lymphoproliferative disorders with interferon alla and intravenous gamma globulin. N Engl J Med 1988; 318: 1334.
36. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.
37. Salloum E, Cooper DL, Howe G et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14: 1943-1949.
38. Thomas JA, Cotter F, Hanby AM et al. Epstein-Barr virus-related oral T-cell lymphoma associated with human immunodeficiency virus immunosuppression. Blood 1993; 81: 3350-3356.
39. Hamilton-Dutoit SJ, Raphael M, Audouin J et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 1993; 82: 619-624.
40. Nakanishi M, Kikuta H, Tomizawa K et al. Distinct clonotypic Epstein-Barr virus-induced fatal lymphoproliferative disorder in a patient with Wiskott-Aldrich syndrome. Cancer 1993; 72: 1376-1381.
41. Okano M, Nakanishi M, Taguchi Y et al. Primary immunodeficiency diseases and Epstein-Barr virus-induced lymphoproliferative disorders. Acta Paediatr Jpn 1992; 34: 385-392.
42. Okano M, Osato T, Koizumi S et al. Epstein-Barr virus infection and oncogenesis in primary immunodeficiency. AIDS Res, 1986; 2 (Suppl 9): S115-S119.
43. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999; 12: 200-217.
44. Canioni D, Jabado N, MacIntyre E et al. Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria. Histopathology 2001; 38: 146-159.
45. Brandau O, Schuster V, Weiss M et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 1999; 8: 2407-2413.
46. Sander CA, Medeiros LJ, Weiss LM et al. Lymphoproliferative lesions in patients with common variable immunodeficiency syndrome. Am J Surg Pathol 1992; 16: 1170-1182.
47. Falk K, Ernberg I, Sakthivel R et al. Expression of Epstein-Barr virus-encoded proteins and B-cell markers in fatal infectious mononucleosis. Int J Cancer 1990; 46: 976-984.
48. Lindahl T, Klein G, Reedman BM et al. Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer 1974; 13: 764-772.
49. Ziegler JL, Andersson M, Klein G, Henle W. Detection of Epstein-Barr virus DNA in American Burkitt's lymphoma. Int J Cancer 1976; 17: 701-706.
50. Tao Q, Robertson KD, Manns A et al. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue [published erratum appears in Blood 1998; 91: 3091]. Blood 1998; 91: 1373-1381.
51. Neri A, Barriga F, Inghirami G et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 1991; 77: 1092-1095.
52. Rickinson AB, Murray RJ, Brooks J et al. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv 1992; 13: 53-80.
53. Murray RJ, Kurilla MG, Brooks JM et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157-168.
54. Glaser SL, Lin RJ, Stewart SL et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997; 70: 375-382.
55. Jarrett AF, Armstrong AA, Alexander E. Epidemiology of EBV and Hodgkin's lymphoma. Ann Oncol 1996; 7 (Suppl 4): 5-10.
56. Stein H, Hummel M, Marafioti T et al. Molecular biology of Hodgkin's disease. Cancer Surv 1997; 30: 107-123.
57. Jaffe ES, Chan JK, Su IJ et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103-111.
58. Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87: 1207-1210.
59. Borisch B, Hennig I, Laeng RH et al. Association of the subtype 2 of the Epstein-Barr virus with T-cell non-Hodgkin's lymphoma of the midline granuloma type. Blood 1993; 82: 858-864.
60. Ho FC, Choy D, Loke SL et al. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum Pathol 1990; 21: 1041-1050.
61. Lipford EH, Margolick JB, Longo DL et al. Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations. Blood 1988; 72: 1674-1681.
62. Medeiros LJ, Jaffe ES, Chen YY, Weiss LM. Localization of Epstein-Barr viral genomes in angiocentric immunoproliferative lesions. Am J Surg Pathol 1992; 16: 439-447.
63. Miyoshi I, Kubonishi I, Yoshimoto S et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981; 294: 770-771.
64. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031-2035.
65. Yamaguchi K, Takatsuki K. Adult T cell leukaemia-lymphoma. Baillieres Clin Haematol 1993; 6: 899-915.
66. Tokudome S, Tokunaga O, Shimamoto Y et al. Incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan. Cancer Res 1989; 49: 226-228.
67. Murphy EL, Hanchard B, Figueroa JP et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989; 43: 250-253.
68. Seiki M, Eddy R, Shows TB, Yoshida M. Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. Nature 1984; 309: 640-642.
69. Siekevitz M, Feinberg MB, Holbrook N et al. Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I. Proc Natl Acad Sci USA 1987; 84: 5389-5393.
70. Sodroski J, Rosen C, Goh WC, Haseltine W. A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus. Science 1985; 228: 1430-1434.
71. Schreck R, Baeuerle PA. NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene. Mol Cell Biol 1990; 10: 1281-1286.
72. Kim SJ, Kehrl JH, Burton J et al. Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type I tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia. J Exp Med 1990; 172: 121-129.
73. Fujii M, Sassone-Corsi P, Verma IM. c-fos promoter trans-activation by the tax 1 protein of human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1988; 85: 8526-8530.
74. Arima N, Molitor JA, Smith MR et al. Human T-cell leukemia virus type I Tax induces expression of the Rel-related family of kappa B enhancer-binding proteins: evidence for a pretranslational component of regulation. J Virol 1991; 65: 6892-6899.
75. Grassmann R, Berchtold S, Radant I et al. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in Gulture. J Virol 1992; 66: 4570-4575.
76. Takatsuki K, Yamaguchi K, Kawano F et al. Clinical diversity in adult T-cell leukemia-lymphoma. Cancer Res 1985; 45 (9 Suppl): 4644s-4645s.
77. Shimamoto Y, Kikuchi M, Funai N et al. Spontaneous regression in adult T-cell leukemia/lymphoma. Cancer 1993; 72: 735-740.
78. Rosenblatt JD. Human T-lymphotropic virus types I and II. West J Med 1993; 158: 379-384.
79. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982; 218: 571-573.
80. Rosenblatt JD, Giorgi JV, Golde DW et al. Integrated human T-cell leukemia virus II genome in CD8+ T cells from a patient with "atypical" hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders. Blood 1988; 71: 363-369.
81. Loughran TP, Coyle T, Sherman MP et al. Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia. Blood 1992; 80: 1116-1119.
82. Martin MP, Biggar RJ, Hamlin-Green G et al. Large granular lymphocytosis in a patient infected with HTLV-II. AIDS Res Hum Retroviruses 1993; 9: 715-719.
83. Cesarman E, Knowles DM. Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease [published erratum appears in Semin Diagn Pathol 1997; 14: 161-162]. Semin Diagn Pathol 1997; 14: 54-66.
84. Karcher DS, Alkan S. Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease. N Engl J Med 1995; 333: 797-798.
85. Oksenhendler E, Duarte M, Soulier J et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10: 61-67.
86. Soulier J, Grollet L, Oksenhendler E et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86: 1276-1280.
87. Karcher DS, Alkan S. Human herpesvirus-8-associated body cavity-based lymphoma in human immunodeficiency virus-infected patients: a unique B-cell neoplasm. Hum Pathol 1997; 28: 801-808.
88. Rainbow L, Platt GM, Simpson GR et al. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol 1997; 71: 5915-5921.
89. Russo JJ, Bohenzky RA, Chien MC et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996; 93: 14862-14867.
90. Arvanitakis L, Geras-Raaka E, Varma A et al. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997; 385: 347-350.
91. Sarid R, Sato T, Bohenzky RA et al. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997; 3: 293-298.
92. Chang Y, Moore PS, Talbot SJ et al. Cyclin encoded by KS herpesvirus. Nature 1996; 382: 410.
93. Jones D, Ballestas ME, Kaye KM et al. Primary-effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 1998; 339: 444-449.
94. Sjak-Shie NN, Vescio RA, Berenson JR. HHV-8 infection and multiple myeloma. J Leukoc Biol 1999; 66: 357-360.
95. Luppi M, Barozzi P, Maiorana A et al. Human herpesvirus-8 DNA sequences in human immunodeficiency virus-negative angioimmunoblastic lymphadenopathy and benign lymphadenopathy with giant germinal center hyperplasia and increased vascularity. Blood 1996; 87: 3903-3909.
96. Pawlotsky JM, Roudot-Thoraval F, Simmonds P et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995; 122: 169-173.
97. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495.
98. Dammacco FS. The cryoglobulins: an overview. Eur J Clin Invest 2001; 31: 628-638.
99. Ferri C, Monti M, La Civita L et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993; 82: 3701-3704.
100. Misiani R, Bellavita P, Fenili D et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117: 573-577.
101. Silvestri F, Baccarani M. Hepatitis C virus-related lymphomas. Br J Haematol 1997; 99: 475-480.
102. Ivanovski M, Silvestri F, Pozzato G et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998; 91: 2433-2442.
103. Silvestri F, Baccarani M. Hepatitis C virus-related lymphomas. Br J Haematol 1997; 99: 475-480.
104. Sansonno D, Lotesoriere C, Cornacchiulo V et al. Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Blood 1998; 92: 3328-3337.
105. Lerat H, Rumin S, Habersetzer F et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 1998; 91: 3841-3849.
106. De Vita S, Sansonno D, Dolcetti R et al. Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood 1995; 86: 1887-1892.
107. Ferri C, La Civita L, Monti M et al. Can type C hepatitis infection be complicated by malignant lymphoma? Lancet 1995; 346: 1426-1427.
108. Misiani R, Bellavita P, Fenili D et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-756.
109. Dammacco F, Sansonno D, Han JH et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84: 3336-3343.
110. Casato M, Agnello V, Pucillo LP et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90: 3865-3873.
111. Parsonnet J, Hansen S, Rodriguez L et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267-1271.
112. Morgner A, Sutton P, O'Rourke JL et al. Helicobacter-induced expression of Bcl-X(L) in B lymphocytes in the mouse model: a possible step in the development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Int J Cancer 2001; 92: 634-640.
113. Eidt S, Stolte M, Fischer R. Helicobacter pylori gastritis and primary gastric non-Hodgkin's lymphomas. J Clin Pathol 1994; 47: 436-439.
114. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342: 571-574.
115. Isaacson PG. Gastric MALT lymphoma: from concept to cure. Ann Oncol 1999; 10: 637-645.
116. Berger F, Felman P, Sonet A et al. Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. Blood 1994; 83: 2829-2835.
117. Steinbach G, Ford R, Glober G et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999; 131: 88-95.
118. Hammel P, Haioun C, Chaumette MT et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphopla with prominent gastric expression. J Clin Oncol 1995; 13: 2524-2529.
119. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998; 16: 1916-1921.
120. Aarts WM, Willemze R, Bende RJ et al. VH gene analysis of primary cutaneous B-cell lymphomas: evidence for ongoing somatic hypermutation and isotype switching. Blood 1998; 92: 3857-3864.
121. Kutting B, Bonsmann G, Metze D et al. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 1997; 36: 311-314.
122. Isaacson PG. Gastrointestinal lymphomas of T- and B-cell types. Mod Pathol 1999; 12: 151-158.
123. Puri AS, Kumar M, Khan EM et al. Immunoproliferative small intestinal disease: a frequently missed diagnosis. Indian J Gastroenterol 1996; 15: 46-48.
124. Martin IG, Aldoori MI. Immunoproliferative small intestinal disease: Mediterranean lymphoma and alpha heavy chain disease. Br J Surg 1994; 81: 20-24.
125. Azar HA. Cancer in Lebanon and the near East. Cancer 1962; 15: 66-78 (Abstr).
126. Frand VI, Ramot B. Malignant lymphomata: an epidemiological study. Harefuah 1963; 65: 83-86 (Abstr).
127. Novis BH. Primary intestinal lymphoma in South Africa. Israel J Med Sci 1979; 15: 386-389.
128. Nikbin B, Banisadre M, Ala F, Mojtabai A. HLA AW 19, B12 in immunoproliferative small intestinal disease. Gut 1979; 20: 226-228.
129. Smith WJ, Price SK, Isaacson PG. Immunoglobulin gene rearrangement in immunoproliferative small intestinal disease (IPSID). J Clin Pathol 1987; 40: 1291-1297.
130. Haghighi P, Wolf PL. Alpha-heavy chain disease. Clin Lab Med 1986; 6: 477-489.
131. Isaacson PG. Middle Eastern intestinal lymphoma. Semin Diagn Pathol 1985; 2: 210-223.
132. Smith WJ, Price SK, Isaacson PG. Immunoglobulin gene rearrangement in immunoproliferative small intestinal disease (IPSID). J Clin Pathol 1987; 40: 1291-1297.
133. Ben Ayed F, Halphen M, Najjar T et al. Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French Intestinal Lymphoma Study Group. Cancer 1989; 63: 1251-1256.
134. O'Keefe SJ, Winter TA, Newton KA et al. Severe malnutrition associated with alpha-heavy chain disease: response to tetracycline and intensive nutritional support. Am J Gastroenterol 1988; 83: 995-1001.
135. Khojasteh A, Haghshenass M, Haghighi P. Current concepts immunoproliferative small intestinal disease. A "Third-World lesion". N Engl J Med 1983; 308: 1401-1405.
136. Matuchansky C, Cogne M, Lemaire M et al. Nonsecretory alpha-chain disease with immunoproliferative small-intestinal disease. N Engl J Med 1989; 320: 1534-1539.
137. Pellet P, Berger R, Bernheim A et al. Molecular analysis of a t(9;14)(p11;q32) translocation occurring in a case of human alpha heavy chain disease. Oncogene 1989; 4: 653-657.
138. Iuchi K, Aozasa K, Yamamoto S et al. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Summary of clinical and pathological findings in thirty-seven cases. Jpn J Clin Oncol 1989; 19: 249-257.
139. Iuchi K, Ichimiya A, Akashi A et al. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer 1987; 60: 1771-1775.
140. Ibuka T, Fukayama M, Hayashi Y et al. Pyothorax-associated pleural lymphoma. A case evolving from T-cell-rich lymphoid infiltration to overt B-cell lymphoma in association with Epstein-Barr virus. Cancer 1994; 73: 738-744.
141. Fukayama M, Ibuka T, Hayashi Y et al. Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am J Pathol 1993; 143: 1044-1049.
142. Murase T, Tashiro K, Suzuki T et al. Detection of antibodies to Fasciola and Anisakis in Japanese patients with intravascular lymphomatosis. Blood 1998; 92: 2182-2183.
143. Talal N. Sjogren's syndrome: historical overview and clinical spectrum of disease. Rheum Dis Clin North Am 1992; 18: 507-515.
144. Zulman J, Jaffe R, Talal N. Evidence that the malignant lymphoma of Sjgoren's syndrome is a monoclonal B-cell neoplasm. N Engl J Med 1978; 299: 1215-1220.
145. Anderson LG, Talal N. The spectrum of benign to malignant lymphopro-liferation in Sjgoren's syndrome. Clin Exp Immunol 1972; 10: 199-221.
146. Anaya JM, McGuff HS, Banks PM, Talal N. Clinicopathological factors relating malignant lymphoma with Sjgoren's syndrome. Semin Arthritis Rheum 1996; 25: 337-346.
147. Royer B, Cazals-Hatem D, Sibilia J et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997; 90: 766-775.
148. Wright DH, Jones DB, Clark H et al. Is adult-onset coeliac disease due to a low-grade lymphoma of intraepithelial T lymphocytes? Lancet 1991; 337: 1373-1374.
149. Leonard JN, Tucker WF, Fry JS et al. Increased incidence of malignancy in dermatitis herpetiformis. BMJ (Clin Res Ed) 1983; 286: 16-18.
150. Collin P, Reunala T, Pukkala E et al. Coeliac disease-associated disorders and survival. Gut 1994; 35: 1215-1218.
151. Loughran TP, Kadin ME, Deeg HJ. T-cell intestinal lymphoma associated with celiac sprue. Ann Intern Med 1986; 104: 44-47.
152. Collins SM, Hamilton JD, Lewis TD, Laufer I. Small-bowel malabsorption and gastrointestinal malignancy. Radiology 1978; 126: 603-609.
153. Holmes GK, Prior P, Lane MR et al. Malignancy in coeliac disease - effect of a gluten free diet. Gut 1989; 30: 333-338.
154. Isaacson PG. Gastrointestinal lymphoma. Hum Pathol 1994; 25: 1020-1029.
155. Bagdi E, Diss TC, Munson P, Isaacson PG. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood 1999; 94: 260-264.
156. Groh V, Porcelli S, Fabbi M et al. Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med 1989; 169: 1277-1294.
157. Aljurf M, Ezzat A, Musa MO. Emerging role of δγ T-cells in health and disease. Blood Rev 2002; 16: 203-206.
158. Wong KF, Chan JK, Matutes E et al. Hepatosplenic gamma delta T-cell lymphoma. A distinctive aggressive lymphoma type. Am J Surg Pathol 1995; 19: 718-726.
159. Volk HD, Reinke P, Neuhaus K et al. Expansion of a CD3+4-8- TCR alpha/beta-T lymphocyte population in renal allograft recipients. Transplantation 1989; 47: 556-558.
160. Hanson MN, Morrison VA, Peterson BA et al. Posttransplant T-cell lymphoproliferative disorders - an aggressive, late complication of solid-organ transplantation. Blood 1996; 88: 3626-3633.
161. Cooke CB, Krenacs L, Stetler-Stevenson M et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88: 4265-4274.
162. Salhany KE, Feldman M, Peritt D, Nowell PC. Cytotoxic T-lymphocyte differentiation and cytogenetic alterations in gammadelta hepatosplenic T-cell lymphoma and posttransplant lymphoproliferative disorders. Blood 1997; 89: 3490-3491.
163. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1-14.
164. Sood R, Stewart CC, Aplan PD et al. Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998; 91: 3372-3378.
165. Loughran TP, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994; 84: 2164-2170.
166. Ohno Y, Amakawa R, Fukuhara S et al. Acute transformation of chronic large granular lymphocyte leukemia associated with additional chromosome abnormality. Cancer 1989; 64: 63-67.
167. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984; 53: 2515-2524.
168. Isaacson PG. Lymphomas of mucosa-associated lymphoid tissue (MALT). Histopathology 1990; 16: 617-619.
169. Hyjek E, Smith WJ, Isaacson PG. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadenitis. Hum Pathol 1988; 19: 766-776.
170. Nicholson AG, Wotherspoon AC, Jones AL et al. Pulmonary B-cell non-Hodgkin's lymphoma associated with autoimmune disorders: a clinicopathological review of six cases. Eur Respir J 1996; 9: 2022-2025.
171. Teruya-Feldstein J, Temeck BK, Sloas MM et al. Pulmonary malignant lymphoma of mucosa-associated lymphoid tissue (MALT) arising in a pediatric HIV-positive patient. Am J Surg Pathol 1995; 19: 357-363.
172. Kurtin PJ, Myers JL, Adlakha H et al. Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type. Am J Surg Pathol 2001; 25: 997-1008.
173. Neri A, Jakobiec FA, Pelicci PG et al. Immunoglobulin and T cell receptor beta chain gene rearrangement analysis of ocular adnexal lymphoid neoplasms: clinical and biologic implications. Blood 1987; 70: 1519-1529.
174. Jeng YM, Tien HF, Su IJ. Phenytoin-induced pseudolymphoma: reevaluation using modern molecular biology techniques. Epilepsia 1996; 37: 104-107.
175. Schwinghammer TL, Howrie DL. Phenytoin-induced lymphadenopathy. Drug Intell Clin Pharm 1983; 17: 460-462.
176. Lorand IG, Hadler WA, Prigenzi LS. Morphological changes in the lymphoid organs induced by diphenylhydantoin sodium (DPH). Virchows Arch 1976; 372: 81-88.
177. Abbondazo SL, Irey NS, Frizzera G. Dilantin-associated lymphadenopathy. Spectrum of histopathologic patterns. Am J Surg Pathol 1995; 19: 675-686.